Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 7011-7020 Newer>

The Motley Fool December 22, 2010 Seth Jayson	Here's How McKesson Is Making So Much for You With TTM margins all at a five-year high, McKesson looks like it's doing great.
The Motley Fool December 22, 2010 Seth Jayson	Cerner Passes This Key Test For the last fully reported fiscal quarter, Cerner's year-over-year revenue grew 13%, and its AR dropped 1.4%. That looks OK.
Pharmaceutical Executive December 1, 2010 Walter Armstrong	Diabetes: Agonists versus Inhibitors Diabetes is pharma's second-largest global market, worth close to $25 billion and growing by double digits annually, even in the developed world.
Pharmaceutical Executive December 1, 2010 Walter Armstrong	Nicotine Addiction: What Lights Up the Field The market for anti-smoking products exceeds $2 billion, but their superiority over cold-turkey quitting remains controversial.
Pharmaceutical Executive December 1, 2010 Walter Armstrong	Non-Small-Cell Lung Cancer: Targeting Pathways and Patients Although the most common cancer worldwide, lung cancer remains poorly treated, with the highest mortality rate.
Pharmaceutical Executive December 1, 2010 Walter Armstrong	Hyperlipidemia: The Anti-CETPs Redux The crowded cholesterol-control category is the biggest US drug market, with 2010 global sales close to $35 billion, according to IMS Health.
Pharmaceutical Executive December 1, 2010 Walter Armstrong	Acute Coronary Syndrome A new class of anticoagulants is competing to dethrone difficult-to-manage warfarin, long the sole option in the prevention of stroke and other bleeding complications in the 2.5 million US patients with atrial fibrillation.
Pharmaceutical Executive December 1, 2010 Walter Armstrong	Vaccines: Progress in Preventing Bad Bugs Long on the sidelines of pharma R&D, vaccine development is moving to center stage as most of the big pharmas diversify, spreading their risk among the full gamut of revenue sources.
Pharmaceutical Executive December 1, 2010	The Sum of All His Parts: Career Reflections of Europe's Chief Drug Regulator The European Medicines Agency is a unique institution, pursuing a mandate shared with a complex web of national and regional groups, each able to place a distinctive imprint around the delicate task of certifying the safety and efficacy of new drugs.
Pharmaceutical Executive December 1, 2010 Walter Armstrong	Cancer: On Target Once More Over the past year or two, a handful of Phase III failures, including megablockbusters like Avastin and Sutent in trials for all kinds of common tumors, indicate that targeted therapy is generally a blunt instrument.
<Older 7011-7020 Newer> Return to current articles.